Eli Lilly Joins ImmunoGen’s List of Big Pharma Collaborators
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)
Published: 6 Jan-2012
DOI: 10.3833/pdr.v2012.i1.1648 ISSN: 1756-7874
Section: Technology Access
Fulltext:
Abstract
Eli Lilly has gained rights to use ImmunoGen’s maytansinoid targeted antibody payload (TAP) technology to develop a specified number of antibody-drug conjugates for the potential treatment of cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS